Angiotensin ii
Giapreza (angiotensin ii) is a protein pharmaceutical. Angiotensin ii was first approved as Giapreza on 2017-12-21. It is used to treat hypotension in the USA. It has been approved in Europe to treat hypotension and shock. It is known to target type-2 angiotensin II receptor, proto-oncogene Mas, potassium channel subfamily K member 3, and type-1 angiotensin II receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| angiotensin ii | ANDA | 2025-06-04 |
| giapreza | New Drug Application | 2024-11-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Angiotensin Ii Acetate, Giapreza, La Jolla Pharma | |||
| 11219662 | 2037-01-06 | U-3262 | |
| 9220745 | 2034-12-18 | U-2217, U-2218 | |
| 10028995 | 2034-12-18 | U-2338 | |
| 10493124 | 2034-12-18 | U-2679 | |
| 11096983 | 2034-12-18 | U-3211, U-3212 | |
| 11559559 | 2034-12-18 | U-3514 | |
| 9572856 | 2031-07-18 | U-2221 | |
| 9867863 | 2029-12-16 | U-2231 | |
| 10335451 | 2029-12-16 | U-2581 | |
| 10500247 | 2029-12-16 | U-2680, U-2681 | |
| 10548943 | 2029-12-16 | U-2739, U-2740 | |
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01C: Cardiac stimulants excl. cardiac glycosides
— C01CX: Other cardiac stimulants in atc
— C01CX09: Angiotensin ii
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
HCPCS
No data
Clinical
Clinical Trials
341 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 10 | 19 | 13 | 36 | 24 | 100 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 8 | 4 | 12 | 15 | 38 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 3 | 9 | 5 | 14 | 32 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 2 | 5 | 8 | 5 | 20 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 7 | 4 | 5 | 6 | 20 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 2 | 3 | 9 | 5 | 19 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | 1 | 4 | 8 | 3 | 18 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 3 | 2 | 10 | 17 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 3 | — | 5 | 8 | 16 |
| Septic shock | D012772 | — | A48.3 | 1 | 3 | 2 | 6 | 3 | 14 |
Show 68 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | 1 | 2 | — | 4 | 6 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | 1 | 1 | — | 4 | 6 |
| Infections | D007239 | EFO_0000544 | — | 1 | 3 | 1 | — | — | 4 |
| Fibrosis | D005355 | — | — | 1 | 4 | 1 | — | — | 4 |
| Communicable diseases | D003141 | — | — | — | 2 | 1 | — | — | 3 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | 2 | — | — | 3 |
| Toxemia | D014115 | — | — | — | — | 1 | — | 2 | 3 |
| Systolic murmurs | D054160 | — | R01.1 | — | 1 | 1 | — | 1 | 3 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | 1 | 1 | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | 1 | — | — | 2 |
Show 25 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 2 | — | — | 6 | 9 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | 4 | 5 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | 3 | 4 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | 1 | — | — | 3 | 4 |
| Recurrence | D012008 | — | — | — | 1 | — | — | 2 | 3 |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 2 | — | — | 1 | 3 |
| Hereditary nephritis | D009394 | EFO_0004128 | Q87.81 | — | 1 | — | — | 2 | 3 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 3 | — | — | — | 3 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | 1 | — | — | 1 | 2 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 1 | — | — | 1 | 2 |
Show 72 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 5 | — | — | — | 3 | 8 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 3 | 6 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 2 | — | — | — | 1 | 3 |
| Orthostatic intolerance | D054971 | — | — | 2 | — | — | — | 1 | 3 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | 1 | 2 |
| Pure autonomic failure | D054970 | — | — | 2 | — | — | — | — | 2 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 2 | — | — | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renin-angiotensin system | D012084 | — | — | — | — | — | — | 4 | 4 |
| Vasodilation | D014664 | — | — | — | — | — | — | 3 | 3 |
| Left ventricular dysfunction | D018487 | — | — | — | — | — | — | 2 | 2 |
| Pediatric obesity | D063766 | — | — | — | — | — | — | 2 | 2 |
| Eclampsia | D004461 | — | O15 | — | — | — | — | 2 | 2 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 2 | 2 |
| Microcirculation | D008833 | — | — | — | — | — | — | 2 | 2 |
| Ventricular dysfunction | D018754 | — | — | — | — | — | — | 1 | 1 |
| Primary dysautonomias | D054969 | — | — | — | — | — | — | 1 | 1 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
Show 34 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Angiotensin ii |
| INN | angiotensin ii |
| Description | Ile(5)-angiotensin II is an angiotensin II that acts on the central nervous system (PDB entry: 1N9V). It has a role as a human metabolite. It is a tautomer of an Ile(5)-angiotensin II dizwitterion. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 11128-99-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL408403 |
| ChEBI ID | 2719 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | M089EFU921 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Giapreza – Innoviva
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 227,890 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
261 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use